Compare Abeona Therapeutics Inc (ABEO) vs Nasdaq100 ETF (QQQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Nasdaq100 ETF — how do they compare? Abeona Therapeutics Inc trades at $6.51 (market cap $373.32M), while Nasdaq100 ETF trades at $703.56. Which is the better fit depends on your goals.
| ABEO | QQQ | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | — |
52-Week High | $7.23 | $746.16 |
52-Week Low | $4.17 | $552.33 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
QQQ trades at $709.43, down 0.45% on the day, with a bullish technical signal from moving averages but neutral oscillators. Analyst consensus is split evenly between buy and sell recommendations. Recent news highlights SpaceX's inclusion in the Nasdaq-100, potentially adding modest exposure to the ETF. The ETF's performance remains tied to large-cap tech stocks, with historical volatility higher than broader market indices.
Outlook is mixed: technical strength supports near-term upside, but valuation concerns and divided analyst sentiment suggest caution. Key risks include tech sector concentration and macroeconomic pressures. Investment opportunity lies in continued tech leadership, though investors should weigh high volatility against growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →
